Seres Therapeutics (NASDAQ:MCRB) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a strong sell rating in a research report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings downgraded Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Stock Down 14.1%

Shares of NASDAQ MCRB opened at $1.70 on Friday. The business has a fifty day moving average price of $3.27 and a two-hundred day moving average price of $6.78. Seres Therapeutics has a fifty-two week low of $1.68 and a fifty-two week high of $29.98.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.63). The company had revenue of $0.59 million for the quarter, compared to the consensus estimate of $6.35 million. Seres Therapeutics had a negative net margin of 2,209.55% and a negative return on equity of 175.40%. As a group, equities analysts anticipate that Seres Therapeutics will post -6.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Seres Therapeutics stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. 59.34% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.